BLI801 (Braintree Laboratories)

BLI801 is an investigational oral laxative developed by Braintree Laboratories, a subsidiary of Sebela Pharmaceuticals, for the treatment of non-idiopathic constipation, including constipation induced by medications such as opioids. The drug has been evaluated in Phase 2 and Phase 3 clinical trials to assess its safety and efficacy in adults who experience fewer than three spontaneous defecations per week along with symptoms like straining and hard stools. While the specific active ingredient and molecular mechanism of action have not been publicly disclosed, the clinical development program focused on providing a therapeutic option for patients whose constipation is secondary to other medical treatments rather than idiopathic in nature.